Back to results
US 2019/0071456 A1Published application
Crystalline beta-lactamase inhibitor
AssigneeAllecra Therapeutics SAS
InventorsAlessandro Lamonica, Marco Forzatti, Stefano Biondi
Life of this patent
Estimating the term…
Abstract
A crystalline compound of formula (I): The compound of formula (I) is a β-lactamase inhibitor and may be administered in combination with an antibacterial agent for prevention or treatment of bacterial infection.
Claims16
A crystalline compound of formula (I):
- wherein the compound has an XRPD spectrum comprising four or more peaks selected from peaks with 2θ angles of:
- 8.82, 12.07, 14.43, 14.92, 16.26, 18.25, 19.06, 19.78, 20.82 and 23.51±0.1 degrees 20;
- or four or more peaks selected from peaks with 2θ angles of:
- 9.33, 10.73, 14.85, 15.29, 15.77, 16.16, 18.60, 20.12, 21.00 and 23.22±0.1 degrees 2θ;
- or four or more peaks selected from peaks with 2¢ angles of:
- 6.7824, 15.4567, 16.3961, 17.1082, 20.0651, 20.6373, 23.2376, 23.6811, 26.1802 and 32.4753±0.05 degrees 2θ;
- or four or more peaks selected from peaks with 2θ angles of:
- 6.8269, 15.0475, 15.6848, 16.4735, 17.1773, 18.4488, 20.6999, 23.3436, 23.8843 and 25.3818±0.05 degrees 2θ.
5 more elements
A crystalline compound of formula (I):
- wherein the compound has an XRPD spectrum comprising four or more peaks selected from peaks with 2θ angles of:
- 9.37, 10.34, 12.59, 13.17, 15.00, 15.63, 18.51, 19.10, 20.79 and 23.93±0.10 degrees 2θ.
A crystalline compound of formula (I):
- wherein the compound has an XRPD spectrum comprising four or more peaks selected from peaks with 2θ angles of:
- 12.7398, 15.3615, 15.9547, 16.4290, 18.1207, 20.4870, 22.8548, 23.2204, 27.0457, 27.6934 and 32.4785±0.05 degrees 2θ.
Dependencies are inferred from the claim text.